Business Context and Reporting Period
This Form 8-K was filed by Immudyne, Inc. (not Lifemd, Inc.) on November 20, 2017. The report details the entry into a material definitive agreement with JOJ Holdings, LLC ("JOJ").
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the specific transaction described below:
- Transaction Cost: $1,000 cash paid to JOJ.
- Asset Acquired: 1,000,000 shares of Blockchain Industries, Inc.
- Contingent Consideration: Issuance of up to 5,000,000 shares of Immudyne common stock to JOJ, based on future sales proceeds of the acquired Blockchain Industries shares.
Material Changes
The primary material change is the acquisition of 1,000,000 shares of Blockchain Industries, Inc. for nominal cash consideration ($1,000) combined with a significant potential equity issuance. This transaction involves a related party, as Justin Schreiber, a greater than 10% shareholder and board member of Immudyne, is the owner of JOJ.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the inherent nature of the related-party transaction. The agreement is contingent on future sales of the acquired Blockchain Industries shares to trigger the issuance of Immudyne stock.
Investor Verification Checklist
- Verify the full text of the agreement filed as Exhibit 10.1 to understand all terms and conditions.
- Confirm the current market value and liquidity of the 1,000,000 shares of Blockchain Industries, Inc. acquired.
- Assess the potential dilution impact of issuing up to 5,000,000 shares of Immudyne common stock.
- Review the related-party transaction disclosure regarding Justin Schreiber's dual role.